$LENZ News

HC Wainwright & Co. Reiterates Buy on LENZ Therapeutics, Maintains $38 Price Target

LENZ Therapeutics Announces Availability Of VIZZ Through Telehealth Platform

LENZ Therapeutics Eye Drug Profile Supports Blockbuster Opportunity: Analyst

LENZ Therapeutics And Arrotex Pharma Announce Exclusive License And Commercialization Agreement For Arrotex To Register And Commercialize VIZZ For Treatment Of Presbyopia In Australia And New Zealand

LENZ Therapeutics adds China partner for presbyopia drug VIZZ

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

LENZ Therapeutics to Participate in Upcoming Investor Conferences

Things Look Grim For LENZ Therapeutics, Inc. (NASDAQ:LENZ) After Today's Downgrade

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Just Reported And Analysts Have Been Cutting Their Estimates

Citigroup Maintains Buy on LENZ Therapeutics, Lowers Price Target to $20

LENZ Therapeutics Inc (LENZ) Q1 2026 Earnings Call Highlights: Strong Prescription Growth Amid ...

HC Wainwright & Co. Maintains Buy on LENZ Therapeutics, Lowers Price Target to $38

Piper Sandler Downgrades LENZ Therapeutics to Neutral, Lowers Price Target to $12

LENZ Therapeutics Q1 Earnings Call Highlights

LENZ Therapeutics, Inc. (LENZ) Q1 2026 Earnings Call Transcript

LENZ Therapeutics, Inc. (LENZ) Reports Q1 Loss, Beats Revenue Estimates

LENZ Therapeutics (NASDAQ:LENZ) Q1 Report Shows Revenue Beat But Deepening Losses Sink Stock

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

LENZ Therapeutics Q1 EPS $(1.32) Misses $(1.05) Estimate, Sales $1.901M Beat $1.759M Estimate

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference